Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry.

导出 LinkOut

翻译打印收藏纠错

作者： Lars H,Lund ^[1] ; Uwe,Zeymer ^[2] ; Andrew L,Clark ^[3] ; Vivencio,Barrios ^[4] ; Thibaud,Damy ^[5] ; Jaroslaw,Drożdż ^[6] ; Candida,Fonseca ^[7] ; Stefanie,Kalus ^[8] ; Philippe C,Ferber ^[9] ; Cornelia,Koch ^[9] ; Aldo P,Maggioni ^[10] ; ARIADNE investigators

作者单位： Department of Medicine, Karolinska Institutet, And Heart Vascular and Neuro Theme Karolinska University Hospital, Stockholm, Sweden. Electronic address: lars.lund@alumni.duke.edu. ^[1] Klinikum Ludwigshafen and Institut für Herzinfarktforschung, Ludwigshafen-am-Rhein, Germany. ^[2] Castle Hill Hospital, Kingston Upon Hull, United Kingdom. ^[3] University Hospital Ramon y Cajal de Madrid, Madrid, Spain. ^[4] University Hospital Henri Mondor, Créteil, France. ^[5] Medical University of Lodz, Lodz, Poland. ^[6] Hospital de Sao Francisco Xavier, CHLO, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. ^[7] GKM Gesellschaft für Therapieforschung mbH, Munich, Germany. ^[8] Novartis Pharma AG, Basel, Switzerland. ^[9] Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy; Maria Cecilia Hospital, GVM Care & Research, Italy. ^[10]

关键词 Heart failure Left ventricular ejection fraction Real-world Reverse cardiac remodeling Sacubitril/valsartan Trial registration: EUPAS 13835.